Alcon Inc. (ETR:2U3)
74.38
+0.28 (0.38%)
At close: Jun 24, 2025, 5:30 PM CET
Alcon Revenue
Alcon had revenue of $2.47B USD in the quarter ending March 31, 2025, with 0.57% growth. This brings the company's revenue in the last twelve months to $9.93B, up 3.80% year-over-year. In the year 2024, Alcon had annual revenue of $9.91B with 4.82% growth.
Revenue (ttm)
$9.93B
Revenue Growth
+3.80%
P/S Ratio
4.03
Revenue / Employee
$387.71K
Employees
25,599
Market Cap
36.96B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 9.91B | 456.00M | 4.82% |
Dec 31, 2023 | 9.46B | 738.00M | 8.47% |
Dec 31, 2022 | 8.72B | 426.00M | 5.14% |
Dec 31, 2021 | 8.29B | 1.46B | 21.34% |
Dec 31, 2020 | 6.83B | -675.00M | -8.99% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.15B |
Siemens Aktiengesellschaft | 77.82B |
Deutsche Telekom AG | 120.25B |
Allianz SE | 109.03B |
Rheinmetall AG | 10.48B |
Siemens Energy AG | 37.44B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 61.84B |
Siemens Healthineers AG | 23.14B |
Alcon News
- 4 days ago - Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL - Wallstreet:Online
- 4 days ago - Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL - Business Wire
- 16 days ago - Alcon's Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold' - Seeking Alpha
- 21 days ago - LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR - Wallstreet:Online
- 21 days ago - LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR - Business Wire
- 26 days ago - Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
- 27 days ago - US FDA approves Alcon's new dry-eye drug - Reuters
- 27 days ago - Alcon up 4% as FDA approves Tryptyr drops for dry eye - Seeking Alpha